Cell Therapeutics' Wild Week
The following video is part of our "Motley Fool Conversations" series, in which, Andrew Tonner, technology editor and analyst, and David Williamson, health-care editor and analyst, discuss topics across the investing world.
In today's edition, they discuss Cell Therapeutics, which has had a roller coaster of a week. After receiving word that its lead drug candidate, pixantrone, had been accepted for FDA review, shares gained 24%. Unfortunately for investors, the company used the higher share price to announce an equity offering worth $20 million, sending shares plummeting back down. Our Motley Fool analysts discuss the news and examine what approval of pixantrone could mean for investors.
Looking for our prediction for 2012? Check out The Motley Fool's brand new report, "The Motley Fool's Top Stock for 2012." It highlights a company that's revolutionizing commerce in Latin America. You can get instant access to the name of this company by clicking here -- it's free.
At the time this article was published Andrew Tonner and David Williamson own no shares of the companies mentioned here. The Motley Fool owns shares of Dendreon. Try any of our Foolish newsletter servicesfree for 30 days. We Fools don't all hold the same opinions, but we all believe thatconsidering a diverse range of insightsmakes us better investors. The Motley Fool has adisclosure policy.